Dabigatran etexilate and reduction in serum apolipoprotein B

Philip Joseph; Guillaume Pare; Lars Wallentin; Stuart Connolly; Salim Yusuf; Jia Wang; Michael Ezekowitz; John Eikelboom; Agneta Siegbahn; Paul Reilly; Ellison Themeles; Jonas Oldgren

doi:10.1136/heartjnl-2015-307586

Article info

Cardiac risk factors and prevention

Original article

Dabigatran etexilate and reduction in serum apolipoprotein B

Authors

Philip Joseph Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada PubMed articles Google scholar articles
Guillaume Pare Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada PubMed articles Google scholar articles
Lars Wallentin Department of Medical Sciences, Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden PubMed articles Google scholar articles
Stuart Connolly Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada PubMed articles Google scholar articles
Salim Yusuf Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada PubMed articles Google scholar articles
Jia Wang Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada PubMed articles Google scholar articles
Michael Ezekowitz Jefferson Medical College, Wynnewood, Pennsylvania, USA PubMed articles Google scholar articles
John Eikelboom Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada PubMed articles Google scholar articles
Agneta Siegbahn Department of Medical Sciences, Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden PubMed articles Google scholar articles
Paul Reilly Department of Clinical Development and Clinical Biostatistics, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA PubMed articles Google scholar articles
Ellison Themeles Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada PubMed articles Google scholar articles
Jonas Oldgren Department of Medical Sciences, Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden PubMed articles Google scholar articles

Correspondence to Dr Philip G Joseph, Population Health Research Institute, C2 6A DB-CVSRI, 237 Barton St East, Hamilton, Ontario, Canada L8L 2X2; philip.joseph{at}phri.ca

View Full Text

Citation

Joseph P, Pare G, Wallentin L on behalf of the RE-LY Investigators, et al

Dabigatran etexilate and reduction in serum apolipoprotein B

Heart 2016;102:57-62.

Publication history

Received March 18, 2015
Revised July 22, 2015
Accepted August 19, 2015
First published November 9, 2015.

Online issue publication

October 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password